ADC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Archives of Disease in Childhood 1989;64:338-342; doi:10.1136/adc.64.3.338
Copyright © 1989 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sólyom, J
Right arrow Articles by Hughes, I A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sólyom, J
Right arrow Articles by Hughes, I A

Value of selective screening for congenital adrenal hyperplasia in Hungary.

J Sólyom, I A Hughes

Second Department of Paediatrics, Semmelweis University Medical School, Budapest.

Measurement of the 17-hydroxyprogesterone concentration in blood spots was used to identify cases of congenital adrenal hyperplasia among patients with inappropriate virilisation, or salt wasting, or both. Between 1978 and 1986 61 were identified among 707 patients (278 neonates, 204 infants, and 225 children). The incidence of classic congenital adrenal hyperplasia was calculated for a seven year prospective trial period using the blood spot 17-hydroxyprogesterone method in selective screening. There were 38 salt losers and 14 simple virilisers in 968,303 live births, an incidence of congenital adrenal hyperplasia of 1:18,000 in the Hungarian population. Selective screening led to earlier diagnosis of congenital adrenal hyperplasia and a pronounced decrease in mortality. A central laboratory to measure the blood spot 17-hydroxyprogesterone concentrations is valuable for the investigation of patients at risk for congenital adrenal hyperplasia in countries where blood steroid assays are not readily available.





This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
J. Kovacs, F. Votava, G. Heinze, J. Solyom, J. Lebl, Z. Pribilincova, H. Frisch, T. Battelino, and F. Waldhauser
Lessons From 30 Years of Clinical Diagnosis and Treatment of Congenital Adrenal Hyperplasia in Five Middle European Countries
J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2958 - 2964.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1989 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health